Shares of Idenix Pharma Down 7+% After FDA Says Needs Added Time to Review Response Package for IDX184
Idenix (NASDAQ: IDIX) comments were from the JPMorgan Healthcare Conference last night. Idenix said an FDA response should be sometime during Q1.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.